Top Psychiatrists Recommend These ADHD Meds for Anxiety
When managing anxiety or depression, selecting the right medication can significantly influence treatment outcomes. Both medications work by affecting serotonin levels in the brain, yet they have distinct characteristics and side effect profiles. In the comparison of Zoloft vs lexapro, Zoloft may be more energizing and is often used for a broader range of conditions, including OCD and PTSD, while Lexapro is typically favored for its tolerability and fewer interactions. Consulting with a healthcare provider helps determine which option aligns best with individual needs, ensuring a personalized approach to mental health treatment.
Strattera is a non-stimulant medication approved by the FDA for the treatment of ADHD. Unlike traditional stimulants, Strattera works by selectively inhibiting the reuptake of norepinephrine, a neurotransmitter involved in attention and emotional regulation. Because it doesn't act on dopamine in the same way as stimulants, it carries a lower risk of dependency and is often favored for patients with co-occurring anxiety disorders.
Psychiatrists often recommend Strattera for individuals with generalized anxiety disorder (GAD) alongside ADHD because it provides cognitive benefits without worsening anxiety. Many patients find that Strattera helps improve focus while also easing symptoms such as worry, excessive fear, and physical tension.
Originally developed as a treatment for high blood pressure, Intuniv has been repurposed as a non-stimulant ADHD medication, especially effective in children and adolescents. It works by activating alpha-2A adrenergic receptors in the brain, which help regulate attention, impulsivity, and emotional responses.
What sets Intuniv apart is its calming effect. Psychiatrists often prescribe it for patients who experience high levels of emotional reactivity or stress. It can reduce anxiety symptoms like nervousness, sleep problems, and irritability, making it a popular choice for patients with both ADHD and anxiety.
Kapvay, an extended-release form of clonidine, is another non-stimulant option used to treat ADHD, especially in younger patients. Like Intuniv, Kapvay affects the alpha-2 adrenergic receptors, helping to improve attention while also reducing hyperactivity and impulsive behaviors.
Clonidine's sedative properties are particularly beneficial for patients with anxiety-related insomnia. Psychiatrists often recommend Kapvay for individuals who struggle with restlessness, racing thoughts, and trouble sleeping. Because it has a dual effect—calming the body and mind—it's frequently used in patients whose anxiety is physically overwhelming.
Though primarily an antidepressant, Wellbutrin is sometimes used off-label for ADHD treatment. It functions as a norepinephrine-dopamine reuptake inhibitor (NDRI), increasing the levels of both neurotransmitters in the brain. This dual action can enhance focus and reduce symptoms of depression and anxiety.
Wellbutrin is favored by psychiatrists for patients who have mild to moderate ADHD symptoms along with anxiety or depression. It doesn't carry the same side effect profile as stimulants and can be a good alternative for individuals who are sensitive to traditional ADHD medications or who have a history of substance use disorders.
Vyvanse is a stimulant that is commonly prescribed for moderate to severe ADHD. While stimulants are often thought to worsen anxiety, this is not always the case. Many patients report that treating their ADHD symptoms with Vyvanse leads to an overall reduction in anxiety because they can focus better and manage daily tasks more effectively.
Psychiatrists may recommend Vyvanse for patients whose anxiety is primarily a result of unmanaged ADHD. By improving executive function and reducing mental clutter, Vyvanse helps some individuals feel more in control, which indirectly reduces anxiety. However, it must be prescribed cautiously, as it can sometimes increase nervousness or insomnia in sensitive individuals.
Adderall XR is another stimulant that combines two amphetamine salts to target the dopamine and norepinephrine systems in the brain. Like Vyvanse, it's often prescribed for patients with ADHD and co-occurring anxiety—especially when anxiety is secondary to the distress caused by disorganization, forgetfulness, or impulsivity.
Top psychiatrists emphasize the importance of careful monitoring when using Adderall XR in patients with anxiety. While it can lead to significant improvements in focus and performance, it may also cause jitteriness or increased heart rate. For this reason, lower starting doses and close follow-ups are essential.
The decision to use a particular ADHD medication to manage anxiety depends on a variety of factors, including the severity of each condition, the patient's medical history, age, and potential for substance misuse. Non-stimulants are often preferred when anxiety is severe or pre-existing. Stimulants can be helpful when ADHD symptoms are driving the anxiety, but they require more careful titration and supervision.
It's also important to note that medication is just one piece of the puzzle. Psychiatrists often recommend combining pharmacological treatment with cognitive behavioral therapy (CBT), mindfulness practices, and lifestyle modifications for the best outcomes. Diet, sleep, and exercise all play crucial roles in regulating mood and attention.
Top psychiatrists understand that treating ADHD and anxiety together requires a balanced and thoughtful approach. While medications like Strattera, Intuniv, Kapvay, Wellbutrin, Vyvanse, and Adderall XR all offer potential benefits, the best choice depends on the individual's unique profile. A comprehensive evaluation by a licensed psychiatrist is essential for selecting the most effective and safest option. With the right treatment plan in place, many patients experience significant relief from both ADHD and anxiety symptoms—leading to better focus, improved emotional regulation, and a higher quality of life.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
17 minutes ago
- New York Times
What Happens When Doctors Can't Trust the Government?
The other day I was talking to one of my patients about her vaccinations, and I noticed that she hadn't had a Covid-19 vaccine since the early days of the pandemic. 'The virus has changed so much since then,' I told her, 'so we recommend that you get the current vaccine——' And then I stopped dead in my tracks, the words 'we recommend' lingering in the air. This is how I'd always phrased these types of recommendations, but I was suddenly unsure of who the 'we' was. Up until recently, it meant a medical community that included not just my health care colleagues, but also the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health, respected medical journals and the research community. It's not remotely feasible for practicing clinicians to review every medical study out there, so we rely on trusted colleagues and institutions with the relevant expertise to help guide us. The 'we' suddenly rang hollow. The institutions I trusted to be deliberative and evidence-based sources of knowledge that extend my medical abilities are no longer that. In the first Trump administration, despite relentless attacks from the president, the nation's public health institutions remained largely intact, if wearied. But the plunder of the second Trump administration has disemboweled them and installed fox-guarding-the-henhouse leadership. Medical professionals can no longer fully trust federal health guidance, and our patients are the ones who will suffer the most. For most of my colleagues and me, the C.D.C. and the N.I.H. were the medical Mount Olympus, the towering pillars of medical authority. Contrary to right-wing portrayals, these were not dictatorial authorities. These were earned authorities, comprising our best, brightest and most dedicated peers. The formidable talents of these doctors and scientists would have commanded enviable salaries had they taken jobs in industry, but they chose the public sector instead — something that we clinicians were forever grateful for. Were there egos, missteps and shortcomings? Sure. But by and large, the people I met who worked for the C.D.C. or N.I.H. were brilliant and rigorous, and cared passionately about the science they were pursuing. While there are some doctors who viewed our public health institutions with disdain — some of them now are running these very organizations — most practicing physicians relied heavily on them to deliver the best care possible to their patients, despite occasional quibbles. What a relief, I always felt, that there were people organizing the things I can't do — testing new treatments, conducting population studies, keeping tabs on worldwide diseases, issuing guidelines and more. Want all of The Times? Subscribe.
Business Insider
11 hours ago
- Business Insider
Sarepta says eight-year-old death deemed unrelated to Elevidys
Sarepta (SRPT) said in a statement Friday night: 'Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy patient who had received Elevidys gene therapy. The death of this patient was deemed unrelated to treatment with Elevidys…Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. Elevidys is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy.' Elevate Your Investing Strategy:
New York Post
11 hours ago
- New York Post
Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory
In a stunning scientific discovery, researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. And the best part of all? Both are already FDA-approved — albeit for cancer. Researchers first pinpointed how Alzheimer's disease scrambles gene activity in individual brain cells. 3 Researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. Pixel-Shot – Using the Connectivity Map database of 1,300 FDA‑approved drugs, the researchers looked for medications that reverse Alzheimer's‑associated gene expression — landing on a shortlist of five, and zeroing in on two cancer drugs. In what one researcher called a 'mock clinical trial,' they then mined 1.4 million patients' medical records, finding that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer's. When given together in an aggressive Alzheimer's mouse model, letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Most importantly, they restored memory and learning in mice that had already developed severe symptoms. It's an exciting development for an illness that's notoriously tricky. 3 Letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Eric Hood – 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,' Marina Sirota, the interim director of the UCSF Bakar Computational Health Sciences Institute, said in a statement. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. 'This makes it very challenging for drug development — which traditionally produces one drug for a single gene or protein that drives disease.' 3 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. yurakrasil – The findings were published in the journal Cell. Both drugs are already FDA‑approved for other uses, which could dramatically speed up the path to human trials. However, because they are cancer drugs, repurposing them may be complex and risky. This finding adds to a growing number of potential Alzheimer's treatments. A compound found in rosemary and sage — carnosic acid — has been shown to reverse memory loss and reduce brain inflammation in mice with Alzheimer's, bringing their cognitive function back to near-normal levels. A study from Stanford Medicine found that seniors who received the shingles vaccine were 20% less likely to develop dementia over seven years. And researchers at Penn State and Stanford University discovered that a certain cancer drug could restore memory and brain function in early stage Alzheimer's models.
